Details
Stereochemistry | ACHIRAL |
Molecular Formula | C14H19Cl2NO2 |
Molecular Weight | 304.2126 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C(Cc1ccc(cc1)N(CCCl)CCCl)CC(=O)O
InChI
InChIKey=JCKYGMPEJWAADB-UHFFFAOYSA-N
InChI=1S/C14H19Cl2NO2/c15-8-10-17(11-9-16)13-6-4-12(5-7-13)2-1-3-14(18)19/h4-7H,1-3,8-11H2,(H,18,19)
Molecular Formula | C14H19Cl2NO2 |
Molecular Weight | 304.2126 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Chlorambucil is a bifunctional 12 alkylating agent of the nitrogen mustard type that has been found active against selected human 13 neoplastic diseases. Chlorambucil alkylates and cross-links DNA during all phases of the cell cycle, inducing DNA damage via three different methods of covalent adduct generation with double-helical DNA. Bone marrow suppression (anemia, neutropenia, thrombocytopenia) is the most commonly occurring side effect of chlorambucil. There are no known drug/drug interactions with chlorambucil.
CNS Activity
Sources: http://www.ncbi.nlm.nih.gov/pubmed/3342460
Curator's Comment:: Data in rats only. Chlorambucil is ionized at physiological pH and thus minimally enters brain, with a brain/plasma concentration of only 0.02.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2311221 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | LEUKERAN Approved UseLEUKERAN (chlorambucil) is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin’s disease. It is not curative in any of these disorders but may produce clinically useful palliation. Launch Date-4.036608E11 |
|||
Primary | LEUKERAN Approved UseLEUKERAN (chlorambucil) is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin’s disease. It is not curative in any of these disorders but may produce clinically useful palliation. Launch Date-4.036608E11 |
|||
Primary | LEUKERAN Approved UseLEUKERAN (chlorambucil) is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin’s disease. It is not curative in any of these disorders but may produce clinically useful palliation. Launch Date-4.036608E11 |
|||
Primary | LEUKERAN Approved UseLEUKERAN (chlorambucil) is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin’s disease. It is not curative in any of these disorders but may produce clinically useful palliation. Launch Date-4.036608E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.46 μg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/6489421 |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
CHLORAMBUCIL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
259 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/6840176 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
CHLORAMBUCIL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.99 μg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/6489421 |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
CHLORAMBUCIL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
380 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/6840176 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
CHLORAMBUCIL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.94 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/6489421 |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
CHLORAMBUCIL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1% |
CHLORAMBUCIL plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
3.2 mg/kg single, oral Overdose Dose: 3.2 mg/kg Route: oral Route: single Dose: 3.2 mg/kg Sources: |
healthy, 1.8 n = 1 Health Status: healthy Age Group: 1.8 Sex: F Population Size: 1 Sources: |
Disc. AE: Irritability, Myoclonic jerks... AEs leading to discontinuation/dose reduction: Irritability Sources: Myoclonic jerks Exaggerated startle response Vomiting Bone marrow depression (mild) Abnormal EEG |
5 mg/kg single, oral Overdose Dose: 5 mg/kg Route: oral Route: single Dose: 5 mg/kg Sources: Page: p.239 |
healthy, 2.5 n = 1 Health Status: healthy Age Group: 2.5 Sex: M Population Size: 1 Sources: Page: p.239 |
Disc. AE: Convulsive seizure, Comatose... AEs leading to discontinuation/dose reduction: Convulsive seizure Sources: Page: p.239Comatose Vomiting |
250 mg single, oral Overdose Dose: 250 mg Route: oral Route: single Dose: 250 mg Co-administed with:: cimetidine, p.o(600 mg; single) Sources: aspirin |
healthy, 38 n = 1 Health Status: healthy Age Group: 38 Sex: M Population Size: 1 Sources: |
Disc. AE: Acute renal failure, Seizures... AEs leading to discontinuation/dose reduction: Acute renal failure Sources: Seizures |
0.2 mg/kg 1 times / day multiple, oral (max) Recommended Dose: 0.2 mg/kg, 1 times / day Route: oral Route: multiple Dose: 0.2 mg/kg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Chronic lymphatic leukemia|Malignant lymphomas Sources: Page: p.1 |
Disc. AE: Bone marrow depression, Carcinogenicity... AEs leading to discontinuation/dose reduction: Bone marrow depression Sources: Page: p.1Carcinogenicity Infertility |
0.2 mg/kg 1 times / day multiple, oral (max) Recommended Dose: 0.2 mg/kg, 1 times / day Route: oral Route: multiple Dose: 0.2 mg/kg, 1 times / day Sources: Page: p.2 |
unhealthy Health Status: unhealthy Condition: Chronic lymphatic leukemia|Malignant lymphomas Sources: Page: p.2 |
Disc. AE: Convulsions, Metastases... AEs leading to discontinuation/dose reduction: Convulsions Sources: Page: p.2Metastases Leukemia |
0.2 mg/kg 1 times / day multiple, oral (max) Recommended Dose: 0.2 mg/kg, 1 times / day Route: oral Route: multiple Dose: 0.2 mg/kg, 1 times / day Sources: Page: p.3 |
unhealthy Health Status: unhealthy Condition: Chronic lymphatic leukemia|Malignant lymphomas Sources: Page: p.3 |
Disc. AE: Skin rash, Erythema multiforme... AEs leading to discontinuation/dose reduction: Skin rash (rare) Sources: Page: p.3Erythema multiforme (rare) Toxic epidermal necrolysis (rare) Stevens-Johnson syndrome (rare) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Abnormal EEG | Disc. AE | 3.2 mg/kg single, oral Overdose Dose: 3.2 mg/kg Route: oral Route: single Dose: 3.2 mg/kg Sources: |
healthy, 1.8 n = 1 Health Status: healthy Age Group: 1.8 Sex: F Population Size: 1 Sources: |
Exaggerated startle response | Disc. AE | 3.2 mg/kg single, oral Overdose Dose: 3.2 mg/kg Route: oral Route: single Dose: 3.2 mg/kg Sources: |
healthy, 1.8 n = 1 Health Status: healthy Age Group: 1.8 Sex: F Population Size: 1 Sources: |
Irritability | Disc. AE | 3.2 mg/kg single, oral Overdose Dose: 3.2 mg/kg Route: oral Route: single Dose: 3.2 mg/kg Sources: |
healthy, 1.8 n = 1 Health Status: healthy Age Group: 1.8 Sex: F Population Size: 1 Sources: |
Myoclonic jerks | Disc. AE | 3.2 mg/kg single, oral Overdose Dose: 3.2 mg/kg Route: oral Route: single Dose: 3.2 mg/kg Sources: |
healthy, 1.8 n = 1 Health Status: healthy Age Group: 1.8 Sex: F Population Size: 1 Sources: |
Vomiting | Disc. AE | 3.2 mg/kg single, oral Overdose Dose: 3.2 mg/kg Route: oral Route: single Dose: 3.2 mg/kg Sources: |
healthy, 1.8 n = 1 Health Status: healthy Age Group: 1.8 Sex: F Population Size: 1 Sources: |
Bone marrow depression | mild Disc. AE |
3.2 mg/kg single, oral Overdose Dose: 3.2 mg/kg Route: oral Route: single Dose: 3.2 mg/kg Sources: |
healthy, 1.8 n = 1 Health Status: healthy Age Group: 1.8 Sex: F Population Size: 1 Sources: |
Comatose | Disc. AE | 5 mg/kg single, oral Overdose Dose: 5 mg/kg Route: oral Route: single Dose: 5 mg/kg Sources: Page: p.239 |
healthy, 2.5 n = 1 Health Status: healthy Age Group: 2.5 Sex: M Population Size: 1 Sources: Page: p.239 |
Convulsive seizure | Disc. AE | 5 mg/kg single, oral Overdose Dose: 5 mg/kg Route: oral Route: single Dose: 5 mg/kg Sources: Page: p.239 |
healthy, 2.5 n = 1 Health Status: healthy Age Group: 2.5 Sex: M Population Size: 1 Sources: Page: p.239 |
Vomiting | Disc. AE | 5 mg/kg single, oral Overdose Dose: 5 mg/kg Route: oral Route: single Dose: 5 mg/kg Sources: Page: p.239 |
healthy, 2.5 n = 1 Health Status: healthy Age Group: 2.5 Sex: M Population Size: 1 Sources: Page: p.239 |
Acute renal failure | Disc. AE | 250 mg single, oral Overdose Dose: 250 mg Route: oral Route: single Dose: 250 mg Co-administed with:: cimetidine, p.o(600 mg; single) Sources: aspirin |
healthy, 38 n = 1 Health Status: healthy Age Group: 38 Sex: M Population Size: 1 Sources: |
Seizures | Disc. AE | 250 mg single, oral Overdose Dose: 250 mg Route: oral Route: single Dose: 250 mg Co-administed with:: cimetidine, p.o(600 mg; single) Sources: aspirin |
healthy, 38 n = 1 Health Status: healthy Age Group: 38 Sex: M Population Size: 1 Sources: |
Bone marrow depression | Disc. AE | 0.2 mg/kg 1 times / day multiple, oral (max) Recommended Dose: 0.2 mg/kg, 1 times / day Route: oral Route: multiple Dose: 0.2 mg/kg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Chronic lymphatic leukemia|Malignant lymphomas Sources: Page: p.1 |
Carcinogenicity | Disc. AE | 0.2 mg/kg 1 times / day multiple, oral (max) Recommended Dose: 0.2 mg/kg, 1 times / day Route: oral Route: multiple Dose: 0.2 mg/kg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Chronic lymphatic leukemia|Malignant lymphomas Sources: Page: p.1 |
Infertility | Disc. AE | 0.2 mg/kg 1 times / day multiple, oral (max) Recommended Dose: 0.2 mg/kg, 1 times / day Route: oral Route: multiple Dose: 0.2 mg/kg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Chronic lymphatic leukemia|Malignant lymphomas Sources: Page: p.1 |
Convulsions | Disc. AE | 0.2 mg/kg 1 times / day multiple, oral (max) Recommended Dose: 0.2 mg/kg, 1 times / day Route: oral Route: multiple Dose: 0.2 mg/kg, 1 times / day Sources: Page: p.2 |
unhealthy Health Status: unhealthy Condition: Chronic lymphatic leukemia|Malignant lymphomas Sources: Page: p.2 |
Leukemia | Disc. AE | 0.2 mg/kg 1 times / day multiple, oral (max) Recommended Dose: 0.2 mg/kg, 1 times / day Route: oral Route: multiple Dose: 0.2 mg/kg, 1 times / day Sources: Page: p.2 |
unhealthy Health Status: unhealthy Condition: Chronic lymphatic leukemia|Malignant lymphomas Sources: Page: p.2 |
Metastases | Disc. AE | 0.2 mg/kg 1 times / day multiple, oral (max) Recommended Dose: 0.2 mg/kg, 1 times / day Route: oral Route: multiple Dose: 0.2 mg/kg, 1 times / day Sources: Page: p.2 |
unhealthy Health Status: unhealthy Condition: Chronic lymphatic leukemia|Malignant lymphomas Sources: Page: p.2 |
Erythema multiforme | rare Disc. AE |
0.2 mg/kg 1 times / day multiple, oral (max) Recommended Dose: 0.2 mg/kg, 1 times / day Route: oral Route: multiple Dose: 0.2 mg/kg, 1 times / day Sources: Page: p.3 |
unhealthy Health Status: unhealthy Condition: Chronic lymphatic leukemia|Malignant lymphomas Sources: Page: p.3 |
Skin rash | rare Disc. AE |
0.2 mg/kg 1 times / day multiple, oral (max) Recommended Dose: 0.2 mg/kg, 1 times / day Route: oral Route: multiple Dose: 0.2 mg/kg, 1 times / day Sources: Page: p.3 |
unhealthy Health Status: unhealthy Condition: Chronic lymphatic leukemia|Malignant lymphomas Sources: Page: p.3 |
Stevens-Johnson syndrome | rare Disc. AE |
0.2 mg/kg 1 times / day multiple, oral (max) Recommended Dose: 0.2 mg/kg, 1 times / day Route: oral Route: multiple Dose: 0.2 mg/kg, 1 times / day Sources: Page: p.3 |
unhealthy Health Status: unhealthy Condition: Chronic lymphatic leukemia|Malignant lymphomas Sources: Page: p.3 |
Toxic epidermal necrolysis | rare Disc. AE |
0.2 mg/kg 1 times / day multiple, oral (max) Recommended Dose: 0.2 mg/kg, 1 times / day Route: oral Route: multiple Dose: 0.2 mg/kg, 1 times / day Sources: Page: p.3 |
unhealthy Health Status: unhealthy Condition: Chronic lymphatic leukemia|Malignant lymphomas Sources: Page: p.3 |
PubMed
Title | Date | PubMed |
---|---|---|
Carcinoma of the urinary bladder in patients receiving cyclophosphamide. | 1975 Aug 7 |
|
Treatment of membranous nephropathy. | 2001 |
|
Potential new therapeutic options in Behçet's syndrome. | 2001 |
|
[Treatment of uveitis with immunosuppressives: antimetabolites and alkylating agents]. | 2001 |
|
Severe bone marrow failure associated with the use of alternating steroid with chlorambucil in lupus membranous nephropathy in Chinese. | 2001 |
|
Esters of chlorambucil with 2-substituted 1,4-dihydroxy-9,10-anthraquinones as multifunctional anticancer agents. | 2001 Apr |
|
[Renal involvement in Waldenstroms macroglobulinemia. Case report and review of the literature]. | 2001 Apr |
|
Treatment of Behçet's disease--an update. | 2001 Apr |
|
Fludarabine for chronic lymphocytic leukemia. | 2001 Apr 12 |
|
Fludarabine for chronic lymphocytic leukemia. | 2001 Apr 12 |
|
Reactions of N,N-bis(2-chloroethyl)-p-aminophenylbutyric acid (chlorambucil) with 2'-deoxyguanosine. | 2001 Aug |
|
Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. | 2001 Aug 15 |
|
Waldenström's macroglobulinemia: clinical course and prognostic factors in 60 patients. Experience from a single hematology unit. | 2001 Dec |
|
The Chinese hamster FANCG/XRCC9 mutant NM3 fails to express the monoubiquitinated form of the FANCD2 protein, is hypersensitive to a range of DNA damaging agents and exhibits a normal level of spontaneous sister chromatid exchange. | 2001 Dec |
|
Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases. | 2001 Dec |
|
Granulomatous slack skin: a distinct disorder or a variant of mycosis fungoides? | 2001 Jan-Feb |
|
Bcl-2 antisense oligonucleotides enhance the cytotoxicity of chlorambucil in B-cell chronic lymphocytic leukaemia cells. | 2001 Jul |
|
Cutaneous xanthomas with concurrent demodicosis and dermatophytosis in a cat. | 2001 Jul |
|
The effect of optimal treatment on elderly patients with aggressive non-Hodgkin's lymphoma: more patients treated with unaffected response rates. | 2001 Jul |
|
Genetic damage by bifunctional agents in repair-active pre-meiotic stages of Drosophila males. | 2001 Jul 1 |
|
A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma. | 2001 Jul 6 |
|
Treatment options in Waldenström's macroglobulinaemia: the role of the purine analogues. | 2001 Jun |
|
UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanism. | 2001 Jun |
|
The cell transmembrane pH gradient in tumors enhances cytotoxicity of specific weak acid chemotherapeutics. | 2001 Jun 15 |
|
[Chronic lymphatic leukemia. 3. The concrete case]. | 2001 Jun 8 |
|
Acquired Factor VIII autoantibody: four cases demonstrating the heterogenous nature of this condition and problems involved in diagnosis and treatment. | 2001 Mar |
|
A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. | 2001 Mar |
|
Immunosuppressive and cytotoxic drugs in the treatment of rheumatic skin disorders. | 2001 Mar |
|
Chlorambucil drug resistance in chronic lymphocytic leukemia: the emerging role of DNA repair. | 2001 Mar |
|
Synthesis, molecular modelling, and antiproliferative and cytotoxic effects of carbocyclic derivatives of distamycin with chlorambucil moiety. | 2001 May |
|
Hypercalcaemia associated with chronic lymphocytic leukaemia in a Giant Schnauzer. | 2001 May |
|
Does intensive treatment with high dose chlorambucil and prednisone as first line and cladribine as second line influence the survival of the patients with chronic lymphocytic leukemia? | 2001 May |
|
Treatment of myelopathy in Sjögren syndrome with a combination of prednisone and cyclophosphamide. | 2001 May |
|
Induction of mutant lymphocytes in cyclophosphamide- and chlorambucil-treated patients. | 2001 May |
|
Immunosuppressive agents in childhood nephrotic syndrome: a meta-analysis of randomized controlled trials. | 2001 May |
|
Novel treatment strategies in chronic lymphocytic leukemia. | 2001 May |
|
[Pneumonia in patients with chronic lymphocytic leukemia. Study of 30 episodes]. | 2001 May 26 |
|
Response to fludarabine in B-cell chronic lymphocytic leukemia patients previously treated with chlorambucil as up-front therapy and a CHOP-like regimen as second line therapy. | 2001 Nov |
|
A novel kind of antitumour drugs using sulfonamide as parent compound. | 2001 Nov-Dec |
|
Sequence-specific DNA cleavage by dipeptides disubstituted with chlorambucil and 2,6-dimethoxyhydroquinone-3-mercaptoacetic acid. | 2001 Nov-Dec |
|
Characteristic and controlled release of anticancer drug loaded poly (D,L-lactide) microparticles prepared by spray drying technique. | 2001 Nov-Dec |
|
Autologous plasma activates Akt/protein kinase B and enhances basal survival and resistance to DNA damage-induced apoptosis in B-chronic lymphocytic leukaemia cells. | 2001 Sep |
|
A case of Behćet's disease complicated by visceral Leishmaniasis and myelodysplasia: clinical considerations. | 2001 Sep |
|
Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue. | 2001 Sep 1 |
|
Novel bicistronic retroviral vector expressing gamma-glutamylcysteine synthetase and the multidrug resistance protein 1 (MRP1) protects cells from MRP1-effluxed drugs and alkylating agents. | 2001 Sep 20 |
|
Chronic lymphocytic leukaemia. | 2001 Sep-Oct |
|
Cutaneous necrobiotic xanthogranuloma (NXG)--successfully treated with low dose chlorambucil. | 2001 Sep-Oct |
|
Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy. | 2002 Jan |
|
Sciatica or spinal lymphoma. | 2002 Jan |
|
A 6-bp deletion in the Crygc gene leading to a nuclear and radial cataract in the mouse. | 2002 Jan |
Sample Use Guides
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/1739612
Curator's Comment:: Chronic lymphocytic leukaemia cells were treated
The inhibition of 3H-thymidine incorporation into the DNA of mitogen-stimulated lymphocytes from patients with chronic lymphocytic leukaemia by chlorambucil was measured in vitro. For the lymphocytes from the untreated patients the mean ID50 was 3.1 ug/ml.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 20:54:56 UTC 2021
by
admin
on
Fri Jun 25 20:54:56 UTC 2021
|
Record UNII |
18D0SL7309
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LIVERTOX |
189
Created by
admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
|
||
|
NDF-RT |
N0000175558
Created by
admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
|
||
|
NDF-RT |
N0000000236
Created by
admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
|
||
|
NCI_THESAURUS |
C697
Created by
admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
|
||
|
WHO-VATC |
QL01AA02
Created by
admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
|
||
|
WHO-ATC |
L01AA02
Created by
admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
8.2
Created by
admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHLORAMBUCIL
Created by
admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
|
PRIMARY | |||
|
SUB06172MIG
Created by
admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
|
PRIMARY | |||
|
1106001
Created by
admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
|
PRIMARY | USP-RS | ||
|
305-03-3
Created by
admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
|
PRIMARY | |||
|
M3343
Created by
admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
|
PRIMARY | Merck Index | ||
|
305-03-3
Created by
admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
|
PRIMARY | |||
|
206-162-0
Created by
admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
|
PRIMARY | |||
|
7143
Created by
admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
|
PRIMARY | |||
|
CHEMBL515
Created by
admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
|
PRIMARY | |||
|
3026
Created by
admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
|
PRIMARY | |||
|
18D0SL7309
Created by
admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
|
PRIMARY | |||
|
DB00291
Created by
admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
|
PRIMARY | |||
|
2346
Created by
admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
|
PRIMARY | RxNorm | ||
|
2708
Created by
admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
|
PRIMARY | |||
|
603
Created by
admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
|
PRIMARY | |||
|
C362
Created by
admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
|
PRIMARY | |||
|
D002699
Created by
admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
|
PRIMARY | |||
|
588
Created by
admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
|
PRIMARY | |||
|
CHLORAMBUCIL
Created by
admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
|
PRIMARY | Description: A white or almost white, crystalline or slightly granular powder. Solubility: Practically insoluble in water; freely soluble in ethanol (~750 g/l) TS and acetone R. Category: Cytotoxic drug. Storage: Chlorambucil should be kept in a well-closed container, protected from light. Additional information: CAUTION: Chlorambucil must be handled with care, avoiding contact with the skin and inhalation of airborne particles. Definition: Chlorambucil contains not less than 98.0% and not more than 101.0% of C14H19Cl2NO2, calculated with reference to the anhydrous substance. |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
EP
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
USP
|
||
|
TRANSPORTER -> SUBSTRATE | |||
|
BINDER->LIGAND |
BINDING
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT |
Has antineoplastic activity
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
A white or almost white, crystalline or slightly granular powder.
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||